Simple Drug Change Could Save Medicare Hundreds of Millions
Big vials of Alzheimer's drug could cost Medicare $336M
Medicare could be throwing away as much as $336 million worth of a costly Alzheimer's drug each year because the size of vials is too big, UCLA researchers estimate. Why it matters: The findings, published Monday in JAMA Internal Medicine,
Changing Alzheimer's drug vial size might save big money for Medicare
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims.
Alzheimer's: Simple Drug Change Could Save Medicare Hundreds of Millions
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
Change in Alzheimer's Drug Vial Size Could Be Big Money-Saver for Medicare
It is imperative to reduce spending on services that do not improve the health of patients, and this is a prime example of such, given that Medicare is paying for a drug only t
Smaller vial for Alzheimer's drug could save Medicare $366M per year: Study
A new study suggests that Medicare could save up to $366 million annually by introducing a new vial size for Alzheimer's drug lecanemab, which is currently only available in single-use, 500- and 200-milligram vials.
Smaller vial size for Alzheimer's drug could save Medicare hundreds of millions per year
Medicare could save up to 74% of the money lost from discarded Alzheimer's drug lecanemab by the simple introduction of a new vial size that would reduce the amount of unused medication that is thrown away.
FiercePharma2d
Leqembi's vial design could result in hundreds of millions in annual Medicare waste: study
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
The American Journal of Managed Care2d
Discarded Lecanemab Leads to Medicare Drug Waste of Up to $336 Million
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
Experts label TGA’s decision to not register Alzheimer’s drug ‘extremely disappointing’
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
Alzheimer’s treatments enter a new era
An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...
朝日新聞社13d
US approves Alzheimer’s drug that modestly slows disease
The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease's underlying biology. The Food and ...
More kids having seizures after ingesting medications, illicit drugs
The number of U.S. children who suffer seizures after swallowing prescription medications or illicit drugs has doubled in ...
Kerala Man Infected With Rare Bacterial Disease, Murine Typhus; Here’s What You Should Know About It
A man from Kerala experienced severe body pain and fatigue upon seeking medical attention, he was diagnosed with rare ...
BioSpace2d
5 Accelerated Approvals Gone Wrong
Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market.